Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Fixed-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Steady-state Itraconazole and Rifampin on the Single-dose Pharmacokinetics of Lazertinib Tablets in Healthy Adult Participants

Next Previous
Search
Trial Profile

A Phase 1 Open-Label, Fixed-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Steady-state Itraconazole and Rifampin on the Single-dose Pharmacokinetics of Lazertinib Tablets in Healthy Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lazertinib (Primary) ; Itraconazole; Rifampicin
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 24 Mar 2023 Results assessing the Drug-Drug Interaction effect of itraconazole on lazertinib in healthy adult participant, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 25 Feb 2021 Status changed from recruiting to completed.
    • 07 Dec 2020 Planned primary completion date changed from 9 Nov 2020 to 30 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top